| Special Report—The top 10 vaccine companies worldwide Johnson & Johnson signals job cuts amid consumer health separation, inflation pressure J&J, flush with blood cancer assets, cuts one from the pipeline Roche recalls new eye therapy Susvimo on leakage fears, aims for market return 'within a year or so' Philips’ CPAP and BiPAP mask recall stretches to 22M devices, lands Class I FDA label Prosecutor confirms probe into Europe's COVID-19 vaccine purchasing Biogen's ALS ambitions on pause as FDA delays approval decision by 3 months J&J sets sights on $60B in pharma sales by 2025, targets 8 brands to deliver growth Alcon, J&J Vision settle for $75M in contact lens price-fixing case AstraZeneca, FibroGen's roxadustat holds promise for sickle cell disease AstraZeneca, tapping into sustainability issues, launches 'Science Can' campaign ‘The Top Line': Pfizer takes kickback lawsuit to the Supreme Court |
| By Eric Sagonowsky,Angus Liu,Fraiser Kansteiner,Zoey Becker,Kevin Dunleavy What a difference five years—and a global pandemic—can make in reshaping an industry. Our latest profile of the top vaccine players includes twice the number of companies as last time along with a handful of new names. |
|
|
|
By Angus Liu In perhaps the most indirect way, Johnson & Johnson is warning about layoffs ahead. As the company is about to bid farewell to consumer health, it's looking at the opportunity to "rightsize" the infrastructure, CFO Joe Wolk said. |
By Max Bayer J&J has axed an early-stage blood cancer asset amid a shifting of the company's phase 1 roster. It comes as two additional hematological assets were added to the pipeline. |
By Fraiser Kansteiner Just as doctors were starting to cozy up to Roche and Genentech’s new eye drug delivery therapy, the companies are pulling the product from market. |
|
Thursday, October 27, 2022 | 11am ET / 8am PT In this webinar, we talk about why knowing where data comes from matters, how to complement clinical trial data with real-world insights, and how to evaluate real-world data to maximize impact. Register now.
|
|
By Andrea Park Just a few weeks after racking up its fifth Class I recall from the FDA this year, Philips has hit the half-dozen mark. |
By Zoey Becker Europe is bringing out the big guns to sort out the EU's COVID-19 vaccine deals. The European Public Prosecutor's Office has confirmed an ongoing investigation into the acquisition of the coronavirus vaccines following "extremely high" public interest. |
By James Waldron The long and winding road Biogen’s tofersen has taken to FDA approval just got longer, with the agency delaying its decision on the amyotrophic lateral sclerosis drug until April. |
By Zoey Becker With $13.2 billion in pharma sales this quarter, $60 billion in pharma sales by 2025 might seem like a lofty goal. But the company is standing by the projection, citing eight key brands during its third-quarter earnings conference call. |
By Andrea Park More than half a decade after it began, a class-action lawsuit accusing several contact lens manufacturers of anticompetitive price fixing has finally come to a close. |
By Ben Adams Big Pharma companies are huge behemoths that span the globe, employ thousands of people and run hundreds of buildings, trial sites, offices and HQs. |
By Helen Floersh The finding opens the door to the use of proline hydroxylase inhibitors to treat beta thalassemia and sickle cell disease. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
|
|---|
|
|
|
Thursday, October 27, 2022 | 12pm ET / 9am PT Is your brand seeking novel strategies to overcome obstacles in the drug channel and unlock your brand’s unique value? Join Phil Inc and other pharma leaders for a discussion on future of patient access. Register Now.
|
|
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| |
|
